These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773 [TBL] [Abstract][Full Text] [Related]
3. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes. Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682 [TBL] [Abstract][Full Text] [Related]
4. Imprinting status of DLK1 gene in brain tumors and lymphomas. Yin D; Xie D; De Vos S; Liu G; Miller CW; Black KL; Koeffler HP Int J Oncol; 2004 Apr; 24(4):1011-5. PubMed ID: 15010842 [TBL] [Abstract][Full Text] [Related]
5. Altered expression of imprinted genes in Wilms tumors. Hubertus J; Lacher M; Rottenkolber M; Müller-Höcker J; Berger M; Stehr M; von Schweinitz D; Kappler R Oncol Rep; 2011 Mar; 25(3):817-23. PubMed ID: 21174059 [TBL] [Abstract][Full Text] [Related]
6. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Steenman MJ; Rainier S; Dobry CJ; Grundy P; Horon IL; Feinberg AP Nat Genet; 1994 Jul; 7(3):433-9. PubMed ID: 7920665 [TBL] [Abstract][Full Text] [Related]
7. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development. Brown KW; Power F; Moore B; Charles AK; Malik KT Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976 [TBL] [Abstract][Full Text] [Related]
8. High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. Douc-Rasy S; Barrois M; Fogel S; Ahomadegbe JC; Stéhelin D; Coll J; Riou G Oncogene; 1996 Jan; 12(2):423-30. PubMed ID: 8570220 [TBL] [Abstract][Full Text] [Related]
9. Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation. Sullivan MJ; Taniguchi T; Jhee A; Kerr N; Reeve AE Oncogene; 1999 Dec; 18(52):7527-34. PubMed ID: 10602511 [TBL] [Abstract][Full Text] [Related]
10. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. Ravenel JD; Broman KW; Perlman EJ; Niemitz EL; Jayawardena TM; Bell DW; Haber DA; Uejima H; Feinberg AP J Natl Cancer Inst; 2001 Nov; 93(22):1698-703. PubMed ID: 11717330 [TBL] [Abstract][Full Text] [Related]
11. Role of genomic imprinting in Wilms' tumour and overgrowth disorders. Reeve AE Med Pediatr Oncol; 1996 Nov; 27(5):470-5. PubMed ID: 8827076 [TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours. Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133 [TBL] [Abstract][Full Text] [Related]
13. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. Fukuzawa R; Heathcott RW; More HE; Reeve AE J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473 [TBL] [Abstract][Full Text] [Related]
16. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847 [TBL] [Abstract][Full Text] [Related]
17. Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. Xu YQ; Grundy P; Polychronakos C Oncogene; 1997 Mar; 14(9):1041-6. PubMed ID: 9070652 [TBL] [Abstract][Full Text] [Related]
18. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. Bjornsson HT; Brown LJ; Fallin MD; Rongione MA; Bibikova M; Wickham E; Fan JB; Feinberg AP J Natl Cancer Inst; 2007 Aug; 99(16):1270-3. PubMed ID: 17686827 [TBL] [Abstract][Full Text] [Related]
20. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Vu TH; Chuyen NV; Li T; Hoffman AR Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]